750 West Pender Street
Suite 1200
Vancouver, BC V6C 2T8
Canada
604-564-9244
https://www.alphacognition.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Michael E. McFadden | CEO & Director | 655,19k | N/D | 1967 |
Mr. Kenneth Anthony Cawkell B.A., LL.B. | Founder, Special Advisor, Corporate Secretary & Director | 97,23k | N/D | 1951 |
Mr. Donald A. Kalkofen B.A. | Chief Financial Officer | 546,1k | 100,44k | 1964 |
Ms. Lauren D'Angelo M.B.A. | Chief Operating Officer | 466,26k | N/D | 1978 |
Dr. Denis G. Kay Ph.D. | Chief Scientific Officer | 180k | N/D | 1957 |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
L'ISS Governance QualityScore di Alpha Cognition Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.